Health Care Equipment

MircroPort Medbot-B

Shanghai MicroPort Robot Group to Hold Annual General Meeting on June 5, 2026

Goldman Sachs Offers Initial Coverage and Buy Ratings for MicroPort Surgical and J&J Robotics

DBS Analyst Maintains Buy Rating for MicroPort Surgical H Shares with Target Price of HKD 33

MicroPort Surgical Robots-HB 2025 Revenue Up 114.2%, Loss Narrows to 250 Million Yuan

MircroPort Medbot-B released FY2025 Q3 earnings on March 26, 2026 (BJT), with actual revenue of HKD 205.18 M and EPS of HKD -0.0722

MircroPort Medbot-B released FY2025 9 Months earnings on March 26 (BJT), actual revenue HKD 395.4 M, actual EPS HKD -0.1935

MicroPort Medbot-B released FY2025 Q4 earnings on March 26 During-Market BJT, actual revenue HKD 208.72 M, actual EPS HKD -0.0734

MicroPort Medbot-B released FY2025 earnings on March 26 During-Market (BJT), actual revenue HKD 602.3 M (forecast HKD 622.96 M), actual EPS HKD -0.2645 (forecast HKD -0.2698)

MicroPort Medbot-B to Release FY2025 Earnings on March 26 During Market Hours (BJT), Forecast Revenue HKD 633.71 M, EPS HKD -0.2745

JPMorgan Maintains Overweight Rating on MicroPort Surgical with Price Target

MicroPort Surgical's Toumai® Laparoscopic Surgical Robot System Receives Over 200 Orders

Micro-Innovation Robot Announces FY Revenue Growth Exceeding 100%

JPMorgan Downgrades MicroPort Surgical's 2025 Sales Forecast, Maintains 'Overweight' Rating

Microbot Medical-B Sees Adjusted Net Loss Narrowing Sharply

MicroPort Surgical Robots Forecasts 110%-120% Revenue Growth in 2025

MicroPort Robotics Completes the World's First Animal Experiment of Large Model Autonomous Surgery

Medical Biotechnology Sector Returns Down, Breakthroughs in Brain-Computer Interfaces and Surgical Robots

MicroPort Surgical's Bronchoscopy Robot Receives NMPA Approval

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02252

Shanghai MicroPort MedBot (Group) Co., Ltd. plans to implement a new share scheme to replace its existing incentive plans, allowing the granting of new and existing shares and options to eligible participants. This initiative aims to enhance alignment with key stakeholders and support talent retention. The current schemes will be terminated upon approval from shareholders and the Hong Kong listing committee. No shares have been granted under the existing plans. The latest analyst rating for the stock (HK:2252) is a Buy with a price target of HK$45.00.

Tip Ranks

MicroPort MedBot Proposes New Share Scheme to Replace Existing Incentive Plans

Shanghai MicroPort MedBot (Group) Co., Ltd. has scheduled its annual general meeting for June 5, 2026, in Shanghai. Shareholders will review the 2025 annual report and vote on a proposed 20% share issuance and a 10% share buyback mandate. These measures aim to enhance capital structure and support funding needs. The company, listed under HK:2252, focuses on advanced surgical robotics and has a current market cap of HK$28.73B. Analysts rate the stock as a Buy with a price target of HK$45.00.

MicroPort MedBot Sets 2026 AGM With New Capital Mandates on the Table

In the first quarter, Shanghai's total foreign trade imports and exports reached 1.23 trillion yuan, a 21.9% increase year-on-year. The single-month import and export volume in March hit 431.04 billion yuan, setting a new historical record. Exports amounted to 537.37 billion yuan, up 16.3%, while imports reached 690.03 billion yuan, surging 26.6%. Both imports and exports have grown year-on-year for 14 consecutive months, with exports rising for 18 consecutive months, demonstrating the resilience and solid foundation of Shanghai's foreign trade

Wallstreetcn

Shanghai's Foreign Trade Imports and Exports in Q1 Grew by 21.9% Year-on-Year; Industrial and Surgical Robot Exports Doubled

03750

02618

01772

03393

03032

The Hang Seng Index closed at 26,394 points, up 446 points or 1.7%. The Hang Seng Tech Index reported 5,092 points, up 180 points or 3.7%. The total market turnover was HKD 256.228 billion. Major stocks such as Alibaba, Xiaomi, and Tencent all saw increases, with Alibaba rising 5.6%, Xiaomi up 3.8%, and Tencent up 3.6%. CATL and JD LOGISTICS reached new highs, with active trading

AASTOCKS

CATL

JD LOGISTICS

GANFENGLITHIUM

WASION HOLDINGS

HSTECH ETF

Hang Seng Index

Hang Seng TECH Index

BABA-W

Alibaba

XIAOMI-W

Xiaomi Corporation

TENCENT

Tencent

Ganfeng Lithium

Hang Seng China Enterprises Index

MEITUAN

Meituan

BIDU-SW

Baidu

HAIDILAO

NEW ORIENTAL-S

New Oriental EDU & Tech

BYD COMPANY

NTES-S

NetEase

LENOVO GROUP

Lenovo Group

TRIP.COM-S

Trip.com

XPENG-W

XPeng

TINGYI

BEONE MEDICINES

Beigene

BeOne Medicines

KUAISHOU-W

KUAISHOU-WR

DEEPEXI TECH

GUOQUAN

GUOXIA TECH

AUNTEA JENNY

GOFINTECH QUANT

EVERG SERVICES

PONY-W

MININGLAMP-W

MARKETINGFORCE

XUNCE

BABA-WR

Alibaba HK SDR 5to1

XIAOMI-WR

Xiaomi HK SDR 2to1

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

CATL HK SDR 30to1

MEITUAN-WR

Meituan HK SDR 5to1

BIDU-SWR

BYD HK SDR 10to1

BYD Company

BYD Company Limited

BYD COMPANY-R

LENOVO GROUP-R

Trip.com HK SDR 50to1

Pony AI

According to the "All-Day Express," the Hang Seng Index rose by 446 points; the Hang Seng Tech Index increased by 180 points. Alibaba rose by over 5%, Xiaomi Group rose by over 3%, Tencent rose by over 3%. CATL, JD LOGISTICS, GANFENGLITHIUM, MicroPort Medbot-B, and WASION HOLDINGS reached new highs with active trading

MPNGY

BABA

The Hang Seng Index closed at 26,306 points, up 359 points or 1.4%. The Hang Seng Tech Index reported 5,058 points, up 146 points or 3.0%. Alibaba rose 4.6%, closing at HKD 134.5; CATL hit a new high, rising 10.3%, closing at HKD 723; Ganfeng Lithium rose 7.3%, closing at HKD 84.15. Other active stocks including Tencent, Meituan, and Xiaomi also saw varying degrees of increase

CHINARES PHARMA

ASMPT

Direxion FTSE China Bull 3X

KraneShares 2x Long BABA Daily ETF

JIAXIN INTL RES

CARSGEN-B

The Half-Day Express reports that the Hang Seng Index rose by 359 points; the Hang Seng Tech Index increased by 146 points. Alibaba rose by over 4%, while CATL, Ganfeng Lithium, MicroPort Medbot-B, ASMPT, and CHINARES PHARMA reached new highs

02160

688351

00853

02172

159883

562600

159898

688016

Bank of America Securities has lowered the target price for MICROPORT to 13.9 yuan, reiterating a "Buy" rating. It expects total revenue in 2025 to be USD 1.105 billion, with a year-on-year increase of 6% after excluding foreign exchange factors. Its "GloMatrix" platform has achieved breakeven, and revenue for the fiscal year 2025 is expected to grow by 78.8% to 163.9 million yuan. Due to the exclusion of MICROPORT NEURO from the consolidated financial statements, revenue forecasts for 2026 to 2028 have been reduced by 10.9% to 12.9%. At the same time, gross margin forecasts have been raised by 1.9 to 2.1 percentage points, and operating expense ratio forecasts have been raised by 11.5 to 12.6 percentage points

MP CARDIOFLOW-B

MICROPORT EP

MICROPORT

MICROPORT NEURO

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Endovastec

Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating

MicroPort announced its 2025 annual performance, with revenue of USD 1.105 billion, an increase of 7.2% year-on-year; gross profit of USD 635 million, an increase of 10.5%. It recorded a net profit of USD 48.52 million, compared to a loss of USD 214 million in the previous year, turning a loss into a profit; earnings per share of 2.59 cents. No final dividend will be distributed

"Performance" MICROPORT achieved a net profit of USD 48.52 million for the entire year, turning a loss into a profit

DBS analyst Nico Chen has maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, setting a price target of HK$33.00. The rating is supported by the company's rapid overseas growth and improving financials, particularly with its laparoscopic surgical robot, Toumai, which is gaining significant market share. Chen anticipates the company will reach breakeven by 2026, driven by increasing sales and better cost management, despite potential geopolitical challenges.

MedBot: Accelerating Overseas Growth and Path to 2026 Breakeven Support Buy Rating

MircroPort Medbot-B(02252.HK)